{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-021144","form_type":"8-K","ticker":"IMDX","cik":"0001642380","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2024-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.391317+00:00","generated_at":"2026-06-01T09:12:40.915911+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Oncocyte enters employment agreement with CSO; base salary $351,525","bullets":["Employment agreement with Chief Science Officer Ekkehard Schütz effective May 20, 2024; four-year term.","Base salary of $351,525.20; eligible for annual cash bonus of 50% of base salary.","Severance upon termination without cause or good reason includes 12 months base salary, pro-rata bonus, health coverage, and accelerated equity vesting.","Agreement replaces prior Managing Director Service Agreement with Chronix Biomedical GmbH."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-021144","json":"https://secwatch.observer/filing/0001493152-24-021144.json","markdown":"https://secwatch.observer/filing/0001493152-24-021144.md","text":"https://secwatch.observer/filing/0001493152-24-021144.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642380/000149315224021144/0001493152-24-021144-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642380/000149315224021144/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T09:12:40.915911+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}